Akt/Protein Kinase B (PKB) Inhibitors - Analysis by Stages, Drug Class, Company Profile, & Discovery Stage Insights

Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments published by Pharma Proff Akt/PKB inhibitors therapeutics currently exhibits a proliferating pipeline with 23 therapeutic candidates. 

Akt plays a critical role in the regulation of cell’s apoptotic pathway and it is being studied extensively for targeting cancerous cells. Akt inhibitors are therapeutics that obstruct the Akt pathways or Akt enzyme, which play a key role in proliferation of solid tumors or cancer cells. Akt are composed of various AGC kinases present in the cells that have hydrophobic motif at the c-terminus of their catalytic core.

According to the research findings, majority of the drug candidates in the pipeline are being developed to be administered by the oral route. It has been observed that oral route of medications is convenient; available in delayed or rapid release formulation; provides improved patient’s compliance; less risk of systemic infections; and has inexpensive nature. Akt inhibitors through oral route of administration have shown positive results in the clinical studies.

Browse Detailed Report on “Akt/Protein Kinase B (PKB) Inhibitors - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” at: www.pharmaproff.com/report/pkb-inhibitors-pipeline-analysis

The companies who are developing Akt/PKB inhibitors for the treatment of various chronic diseases have shown positive clinical results in the various phases of drug development. For instance, in June 2018, F. Hoffman-La Roche Ltd. announced the interim results of Phase II study (LOTUS) for the drug candidate, ipatasertib, that showed improvement in patients with triple negative breast cancer (TNBC) toward overall survival (OS). This result was presented in the 2018 ASCO Annual Meeting, held in the U.S. The Phase II LOTUS study showed an increase in OS up to 23.1 months (median) in interventional study, as compared to 18.4 months (median) in placebo study.

  

Some of the key players involved in the development of Akt/PKB inhibitors include F. Hoffman-La-Roche Ltd, Eli Lilly & Company, Merck & Co. Inc., Novartis AG, Denovo Biopharma LLC, Diffusion Pharmaceuticals Inc., Astex Pharmaceuticals, ArQule Inc., Cotinga Pharmaceuticals Inc., and Oneness Biotech Co. Ltd.

Read More

Androgenetic Alopecia Therapeutics Pipeline Analysis by Stages, Drug Class, Company Profile, Phase of Development, Clinical Trial & Discovery Stage Insights

Androgenetic Alopecia Therapeutics – Competitive Landscape, Epidemiology Forecast, and Pipeline Analysis, 2019 published by Pharma Proff, androgenetic alopecia therapeutics currently exhibits a proliferating pipeline with 15+ therapeutic candidates.

Androgenetic Alopecia Therapeutics Pipeline Insights

Androgenetic alopecia is a genetic disorder of patterned hair loss that affects both men and women. The disorder shortens hair growth cycle due to excess of androgen, which eventually delays hair growth. Some of the major symptoms include gradual recession of frontal hairline, increased hair fall, bitemporal recession of hair, and thinning of the hair. The symptoms start appearing at the age of 20 and are seen to be prominent in people aged 40 years and above. The disorder leads to hair thinning near crown region, and maybe caused due to various genetic as well as environmental factors. The disorder can also occur due to hormonal imbalance, improper functioning of androgen hormones, poor diet, and excessive smoking.

Request to Get the Sample Pages at: 

Insights into Pipeline Segments

According to the research, many drugs being developed for androgenetic alopecia, which are administered topically. It has been found that topical route of administration is easy to use, non-invasive, and ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive Androgenetic Alopecia Therapeutics Pipeline

There are several companies which have shown positive results of clinical trials. For instance, in February 2019, Cassiopea SpA announced effective result of Phase II clinical trial of Breezula for treatment of androgenetic alopecia.

Browse Detailed Report at: https://www.pharmaproff.com/report/androgenic-alopecia-therapeutics-pipeline-analysis

Technological Advancements Play a Pivotal Role in Androgenetic Alopecia Therapeutics Development

It has been observed that many pharmaceutical companies are developing new and improved technologies for the development of androgenetic alopecia therapeutics. These technologies play an important role in the drug development by helping the companies to develop more specific and effective targeted therapies. For instance, RepliCel Life Sciences is using its proprietary cell therapy technology to develop therapeutic candidates for pattern baldness and other disorders. It utilizes dermal sheath cup cells, which induce the growth of cells in the area of baldness.

Samumed LLC, Brickell Biotech Inc., Aclaris Therapeutics Inc., Cassiopea S.p.A, Kerastem Technologies LLC, Almirall S.A., and RepliCel Life Sciences are the major players involved in the development of drug candidates for the treatment of androgenetic alopecia.

Read More